In the world of investing, quarterly earnings reports serve as critical benchmarks that provide insights into a company\u2019s performance and future potential. Among the figures presented, earnings often take center stage, as they represent the core profitability drivers behind stock prices. When companies beat earnings expectations, they typically see a rise in their valuation. Conversely, failing to meet or exceed expectations can have negative repercussions for stock prices. Investors keen to optimize their portfolios might want to look for stocks that are poised to report positive earnings surprises.<\/p>\n
Finding companies that may exceed earnings estimates is an investment strategy often referred to as hunting for “earnings whispers.” However, pinpointing these opportunities isn\u2019t an easy task. One effective approach to uncover potential earnings surprises is by leveraging the Earnings ESP (Expected Surprise Prediction)<\/strong> model. This innovative tool focuses on the most recent analyst earnings revisions, which tend to be more accurate than earlier estimates.<\/p>\n The ESP model compares the Most Accurate Estimate<\/strong> to the Zacks Consensus Estimate<\/strong>, calculating the percentage difference to generate the Expected Surprise Prediction. Additionally, the Zacks Rank<\/strong> is incorporated into this metric to help identify companies that are likely to outperform their next earnings consensus estimates. Research indicates that when analysts combine a Zacks Rank of #3 (Hold) or higher with a positive Earnings ESP, there\u2019s a 70% probability of a positive surprise. Moreover, this strategy has yielded impressive annual returns averaging around 28.3% over the last decade.<\/p>\n So, which companies should you consider? Let\u2019s take a closer look at two medical stocks that are showing signs of potential earnings surprises. The first is Pfizer (PFE)<\/strong>, currently sitting at a Zacks Rank of #3 (Hold). As of its upcoming earnings release scheduled for October 29, 2024, Pfizer boasts a Most Accurate Estimate<\/strong> of $0.65 per share and an Earnings ESP<\/strong> of +2.68%. This figure is derived from the percentage difference between the Most Accurate Estimate and a Consensus Estimate of $0.64.<\/p>\n Pfizer has been in the news not only for its key role in the COVID-19 vaccine distribution but also for its broader pipeline of products in various therapeutic areas. Given its strong position and expected positive earnings signal, it may be a stock worth keeping on your radar.<\/p>\n The second stock to consider is DexCom (DXCM)<\/strong>, which, like Pfizer, holds a Zacks Rank of #3 (Hold). DexCom is set to report earnings on February 13, 2025. As of now, its Most Accurate Estimate stands at $0.52 per share, while its Consensus Estimate is $0.51, leading to an Earnings ESP of +0.98%. DexCom has solidified itself as a leader in continuous glucose monitoring systems, making it an attractive option for investors interested in the medical technology sector.<\/p>\n Investors looking for promising returns may benefit from focusing on companies like Pfizer and DexCom, both of which showcase positive Earnings ESP metrics. By utilizing the Earnings ESP tool, investors can uncover stocks with strong potential to exceed earnings expectations, thereby enhancing their chances of capturing superior returns.<\/p>\n As the stock market continues to evolve, keeping a keen eye on earnings surprises can be a strategic move for investors. Remember, it\u2019s not just about the numbers \u2014 it\u2019s about understanding the story behind those numbers and leveraging insights effectively to make informed investment decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" Want Better Returns? Don\u2019t Ignore These 2 Medical Stocks Set to Beat Earnings In the world of investing, quarterly earnings reports serve as critical benchmarks that provide insights into a company\u2019s performance and future potential. Among the figures presented, earnings often take center stage, as they represent the core profitability drivers behind stock prices. When…<\/p>\n","protected":false},"author":32,"featured_media":9047,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[685],"tags":[],"class_list":["post-9048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-stocks"],"_links":{"self":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/comments?post=9048"}],"version-history":[{"count":0,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9048\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media\/9047"}],"wp:attachment":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media?parent=9048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/categories?post=9048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/tags?post=9048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Recognizing Potential Earnings Stars<\/h2>\n
Another Contender: DexCom<\/h2>\n
Conclusion: The Importance of Earnings Predictions<\/h2>\n